Clinical Trial Update: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABBV-4083 alone or with albendazole for onchocerciasis; the study was terminated but results were posted in 2024, including assessments…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onchocerciasis

Drugs mentioned

• ABBV-4083

Snippet

Sponsor: AbbVie | Conditions: Onchocerciasis | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19